A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.

Yasuhiro Tsutani, Shozo Ohsumi, Kenjiro Aogi, Naruto Taira, Masaaki Kataoka, Yasushi Hamamoto, Rieko Nishimura, Shigemitsu Takashima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.

Original languageEnglish
Pages (from-to)374-377
Number of pages4
JournalBreast Cancer
Volume13
Issue number4
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

erbB-2 Genes
Gene Amplification
Breast Neoplasms
Neoplasms
Therapeutics
Lung
Ductal Carcinoma
Axilla
Thoracic Wall
Progesterone Receptors
Denmark
Fluorescence In Situ Hybridization
Estrogen Receptors
Cicatrix
Breast
Radiotherapy
Lymph Nodes
Trastuzumab
Staining and Labeling
Neoplasm Metastasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tsutani, Y., Ohsumi, S., Aogi, K., Taira, N., Kataoka, M., Hamamoto, Y., ... Takashima, S. (2006). A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer, 13(4), 374-377.

A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. / Tsutani, Yasuhiro; Ohsumi, Shozo; Aogi, Kenjiro; Taira, Naruto; Kataoka, Masaaki; Hamamoto, Yasushi; Nishimura, Rieko; Takashima, Shigemitsu.

In: Breast Cancer, Vol. 13, No. 4, 2006, p. 374-377.

Research output: Contribution to journalArticle

Tsutani, Y, Ohsumi, S, Aogi, K, Taira, N, Kataoka, M, Hamamoto, Y, Nishimura, R & Takashima, S 2006, 'A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.', Breast Cancer, vol. 13, no. 4, pp. 374-377.
Tsutani, Yasuhiro ; Ohsumi, Shozo ; Aogi, Kenjiro ; Taira, Naruto ; Kataoka, Masaaki ; Hamamoto, Yasushi ; Nishimura, Rieko ; Takashima, Shigemitsu. / A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. In: Breast Cancer. 2006 ; Vol. 13, No. 4. pp. 374-377.
@article{a775b9222c5c42f4847f5368359643b0,
title = "A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.",
abstract = "An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.",
author = "Yasuhiro Tsutani and Shozo Ohsumi and Kenjiro Aogi and Naruto Taira and Masaaki Kataoka and Yasushi Hamamoto and Rieko Nishimura and Shigemitsu Takashima",
year = "2006",
language = "English",
volume = "13",
pages = "374--377",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.

AU - Tsutani, Yasuhiro

AU - Ohsumi, Shozo

AU - Aogi, Kenjiro

AU - Taira, Naruto

AU - Kataoka, Masaaki

AU - Hamamoto, Yasushi

AU - Nishimura, Rieko

AU - Takashima, Shigemitsu

PY - 2006

Y1 - 2006

N2 - An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.

AB - An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=39049184636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049184636&partnerID=8YFLogxK

M3 - Article

C2 - 17146166

AN - SCOPUS:39049184636

VL - 13

SP - 374

EP - 377

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 4

ER -